TAK-700, also known as Orteronel, is primarily used in the treatment of prostate cancer. It functions as a selective inhibitor of the enzyme 17,20-lyase, which plays a crucial role in the production of androgens. By inhibiting this enzyme, TAK-700 effectively reduces the levels of androgens, hormones that can promote the growth of prostate cancer cells. This makes it particularly useful in cases of castration-resistant prostate cancer, where the disease progresses despite low levels of testosterone achieved through other treatments. The application of TAK-700 is often considered in combination with other therapies to enhance its efficacy in controlling the progression of the disease. Its targeted action helps in managing symptoms and slowing down the advancement of prostate cancer, providing a therapeutic option for patients who have limited responses to traditional hormonal therapies.